Synergistic anticancer effects of curcumin and hinokitiol on gefitinib resistant non-small cell lung cancer cells

Tae Bok Lee, Eun Ju Seo, Ji-Yun Lee, Jin Hyun Jun

Research output: Contribution to journalArticle

Abstract

This study evaluated the synergistic effect of curcumin (diferuloylmethane) and hinokitiol (β-thujaplicin), natural product derived phytochemicals, on gefitinib (Iressa) resistant non-small cell lung cancer (NSCLC) cells. Gefitinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. However, gefitinib resistance is easily acquired by NSCLC and followed by the development of progressive disease. Curcumin and hinokitiol are well-known bioactive compounds demonstrating anti-inflammation, anti-bacteria and anticancer effects. However, the effects of co-treatment of curcumin and hinokitiol on cancer cells have not been reported. Here, we postulated, for the first time, the possibility of combination therapy with curcumin and hinokitiol for treatment of gefitinib resistant NSCLC via increment of apoptosis and lysosomal enlargement.

Original languageEnglish
Pages (from-to)1667-1671
Number of pages5
JournalNatural Product Communications
Volume13
Issue number12
Publication statusPublished - 2018 Jan 1

Fingerprint

Curcumin
curcumin
lung neoplasms
Non-Small Cell Lung Carcinoma
cells
phytopharmaceuticals
tyrosine
Phytochemicals
phosphotransferases (kinases)
Biological Products
Epidermal Growth Factor Receptor
apoptosis
inflammation
Protein-Tyrosine Kinases
Lung Neoplasms
therapeutics
antineoplastic activity
neoplasm cells
gefitinib
beta-thujaplicin

Keywords

  • Curcumin
  • Gefitinib
  • Hinokitiol
  • Non-small cell lung cancer (NSCLC)
  • Synergistic effect

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Plant Science
  • Complementary and alternative medicine

Cite this

Synergistic anticancer effects of curcumin and hinokitiol on gefitinib resistant non-small cell lung cancer cells. / Lee, Tae Bok; Seo, Eun Ju; Lee, Ji-Yun; Jun, Jin Hyun.

In: Natural Product Communications, Vol. 13, No. 12, 01.01.2018, p. 1667-1671.

Research output: Contribution to journalArticle

@article{48a671d64e9d4afd8114a8ddbdeda1d8,
title = "Synergistic anticancer effects of curcumin and hinokitiol on gefitinib resistant non-small cell lung cancer cells",
abstract = "This study evaluated the synergistic effect of curcumin (diferuloylmethane) and hinokitiol (β-thujaplicin), natural product derived phytochemicals, on gefitinib (Iressa) resistant non-small cell lung cancer (NSCLC) cells. Gefitinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. However, gefitinib resistance is easily acquired by NSCLC and followed by the development of progressive disease. Curcumin and hinokitiol are well-known bioactive compounds demonstrating anti-inflammation, anti-bacteria and anticancer effects. However, the effects of co-treatment of curcumin and hinokitiol on cancer cells have not been reported. Here, we postulated, for the first time, the possibility of combination therapy with curcumin and hinokitiol for treatment of gefitinib resistant NSCLC via increment of apoptosis and lysosomal enlargement.",
keywords = "Curcumin, Gefitinib, Hinokitiol, Non-small cell lung cancer (NSCLC), Synergistic effect",
author = "Lee, {Tae Bok} and Seo, {Eun Ju} and Ji-Yun Lee and Jun, {Jin Hyun}",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "13",
pages = "1667--1671",
journal = "Natural Product Communications",
issn = "1934-578X",
publisher = "Natural Product Communications",
number = "12",

}

TY - JOUR

T1 - Synergistic anticancer effects of curcumin and hinokitiol on gefitinib resistant non-small cell lung cancer cells

AU - Lee, Tae Bok

AU - Seo, Eun Ju

AU - Lee, Ji-Yun

AU - Jun, Jin Hyun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This study evaluated the synergistic effect of curcumin (diferuloylmethane) and hinokitiol (β-thujaplicin), natural product derived phytochemicals, on gefitinib (Iressa) resistant non-small cell lung cancer (NSCLC) cells. Gefitinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. However, gefitinib resistance is easily acquired by NSCLC and followed by the development of progressive disease. Curcumin and hinokitiol are well-known bioactive compounds demonstrating anti-inflammation, anti-bacteria and anticancer effects. However, the effects of co-treatment of curcumin and hinokitiol on cancer cells have not been reported. Here, we postulated, for the first time, the possibility of combination therapy with curcumin and hinokitiol for treatment of gefitinib resistant NSCLC via increment of apoptosis and lysosomal enlargement.

AB - This study evaluated the synergistic effect of curcumin (diferuloylmethane) and hinokitiol (β-thujaplicin), natural product derived phytochemicals, on gefitinib (Iressa) resistant non-small cell lung cancer (NSCLC) cells. Gefitinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. However, gefitinib resistance is easily acquired by NSCLC and followed by the development of progressive disease. Curcumin and hinokitiol are well-known bioactive compounds demonstrating anti-inflammation, anti-bacteria and anticancer effects. However, the effects of co-treatment of curcumin and hinokitiol on cancer cells have not been reported. Here, we postulated, for the first time, the possibility of combination therapy with curcumin and hinokitiol for treatment of gefitinib resistant NSCLC via increment of apoptosis and lysosomal enlargement.

KW - Curcumin

KW - Gefitinib

KW - Hinokitiol

KW - Non-small cell lung cancer (NSCLC)

KW - Synergistic effect

UR - http://www.scopus.com/inward/record.url?scp=85059574262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059574262&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1667

EP - 1671

JO - Natural Product Communications

JF - Natural Product Communications

SN - 1934-578X

IS - 12

ER -